FranciscoHernandez-IlizaliturriMD

Hematologic Oncology

Director of the Lymphoma Research, Head of the Lymphoma Translational Research Program, Professor of Medical Oncology, Department of Medicine, Roswell Park Cancer Institute. Associate Professor of Medicine, SUNY Buffalo School of Medicine and Biomedical Sciences

Join to view full profile

Dr. Hernandez-Ilizaliturri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hernandez-Ilizaliturri's full profile

Already have an account?

Office
Elm And Carlton St
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-3894

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 1999 - 2002
University at BuffaloResidency, Internal Medicine, 1996 - 1999
Escuela de Medicina Ignacio A. SantosClass of 1995

Certifications & Licensure

NY State Medical License 2003 - 2026

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2011 Dec 06
Completed
Phase 2
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma Start of enrollment: 2007 Apr 17
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2020 Nov 18
Suspended
Phase 1, Phase 2
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Start of enrollment: 2024 Jun 15
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

106 citations
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Blood. 2023-04-06
157 citations
NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun
Journal of the National Comprehensive Cancer Network. 2018-03-01
212 citations
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass
Lancet. 2022-06-18

Abstracts/Posters

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Ce...
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Utility of Bone Marrow Biopsy in the Staging of T-Cell Lymphoma in the PET-CT Era
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Francisco J. Hernandez-Ilizaliturri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)Clinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
High Mir-17-92 Expression Is Associated with in Vitro chemoresistance in Burkitt Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Practice & Performance in Hematologic Oncology 2013
Cvent Online Event Registration Software, Syracuse, New York - 3/23/2013
Join now to see all

Press Mentions

Castle Connolly Names 38 Roswell Park Physicians to ‘Top Doctors’ ListFebruary 2nd, 2023
Roswell Park Oncology Experts Named to Castle Connolly ‘Top Doctors’ ListAugust 4th, 2022
Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual MeetingDecember 11th, 2021
Join now to see all